-
ScienceDaily
May 30, 2015, 10:22 am96 ptsA new phase 3 study in some of the most difficult-to-treat patients, women with endocrine-resistant disease, showed that the newly approved drug, palbociclib, more than doubled the time to cancer recurrence for women with hormone-receptor (HR+) positive metastatic breast cancer.
Trending Today on EcoTopical
Welcome to EcoTopical Your daily eco-friendly green news aggregator.
Leaf through planet Earths environmental headlines in one convenient place. Read, share and discover the latest on ecology, science and green living from the web's most popular sites.
Leaf through planet Earths environmental headlines in one convenient place. Read, share and discover the latest on ecology, science and green living from the web's most popular sites.